Federated Hermes Institutional Trust has submitted a certification regarding its prospectus and statement of additional information, a significant step in maintaining compliance with regulatory standards. This filing, made on October 30, 2026, is crucial for the trust as it assures investors that the information they receive is accurate and up-to-date.
The filing is particularly important as it reflects the trust's commitment to transparency and adherence to the Securities Act of 1933. By certifying that the definitive form of the prospectus does not differ from the previously filed registration statement, Federated Hermes reaffirms its dedication to regulatory compliance.
Background
Federated Hermes Institutional Trust is an investment management company based in Warrendale, Pennsylvania. The trust is known for its various investment funds, including the Federated Hermes Short-Intermediate Total Return Bond Fund. The company operates under the Central Index Key (CIK) 0000925723 and has a fiscal year ending on July 31. Recent filings indicate ongoing activity, including a series of amendments and prospectus updates.
What the Filing Says
The filing states, "Pursuant to Rule 497(j) under the Securities Act of 1933, the above-named Registrant hereby certifies that the definitive form of Prospectus and Statement of Additional Information dated October 31, 2026, does not differ from the form of Prospectus and Statement of Additional Information contained in the Registration Statement for the Fund which was electronically filed..." This certification serves to confirm the consistency of the information provided to investors.
Impact
This filing may affect current and potential investors in the Federated Hermes Short-Intermediate Total Return Bond Fund and other related funds. By ensuring compliance with regulatory requirements, the trust aims to bolster investor confidence and maintain its reputation in the investment management industry.
What's Next
The filing does not say what happens next.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






